Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of July 8, 2025 • 1:01 PM ET

Date/Time Source News Release
07/08/2025 08:00 AM EDT GlobeNewswire Vaxart Announces Trading on OTCQX Best Market
07/08/2025 07:00 AM EDT GlobeNewswire OTC Markets Group Welcomes Vaxart, Inc. to OTCQX
06/13/2025 04:52 PM EDT GlobeNewswire Vaxart Announces Preliminary Results of Annual Meeting of Stockholders
06/11/2025 07:30 AM EDT GlobeNewswire Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
06/10/2025 04:47 PM EDT GlobeNewswire Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
06/02/2025 04:20 PM EDT GlobeNewswire Vaxart Announces Adjournment of Annual Meeting of Stockholders
05/29/2025 04:05 PM EDT GlobeNewswire Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025
05/29/2025 08:00 AM EDT GlobeNewswire Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders
05/28/2025 08:00 AM EDT GlobeNewswire Vaxart Answers Additional Frequently Asked Questions from Retail Investors
05/27/2025 08:00 AM EDT GlobeNewswire Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
Page

Additional News

As of July 8, 2025 • 1:01 PM ET

Date/Time Source News Release
06/11/2025 04:31 PM EDT PRISM News Vaxart's Second-Generation Norovirus Vaccine Shows Stronger Immune Response in Phase 1 Study
06/11/2025 02:30 PM EDT PRISM News PRISM Mid-Day Movers: MedDevice Orders and Device Recognition by Health Insurance Company Drives Indices Higher
06/11/2025 10:18 AM EDT SeekingAlpha Vaxart soars on positive data from new norovirus vaccine trial
05/14/2025 05:26 PM EDT SeekingAlpha Vaxart stock climbs on positive study of pill-based norovirus vaccine
05/13/2025 08:43 PM EDT SeekingAlpha Vaxart signals cash runway into Q1 2026 while advancing COVID-19 and norovirus vaccine programs
05/13/2025 08:43 PM EDT SeekingAlpha Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript
05/13/2025 04:14 PM EDT SeekingAlpha Vaxart GAAP EPS of -$0.07 in-line, revenue of $20.9M
05/13/2025 10:00 AM EDT SeekingAlpha Here are the major earnings after the close today
05/13/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Tuesday, May 13th, 2025
05/13/2025 05:31 AM EDT US Earnings Reports Expected earnings - Vaxart Inc.
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.